Recent evidence suggests that incorporating European mistletoe Viscum album L. (VA) extracts into PD-1/PD-L1 therapy may improve overall survival in patients with advanced or metastatic non-small cell lung cancer (NSCLC) [4,5]. Here, PDCD1 is linked to non-small cell lung carcinoma.